2023年2月至3月土耳其因胃内注射肉毒杆菌神经毒素减重后欧洲四国出现大规模旅行相关医源性肉毒中毒暴发
2023年3月,德国(30例)、瑞士(2例)、奥地利(1例)和法国(1例)共发现34例医源性肉毒中毒相关病例,溯源至在土耳其接受胃内注射肉毒杆菌神经毒素减重治疗。通过欧盟网络和《国际卫生条例》机制发布警报并开展欧洲协作调查,首批12例德国病例中9例经实验室确诊,需采用创新高灵敏内肽酶检测法在患者血清中检出微量毒素。
要点
- 34例医源性肉毒中毒病例分布于德国30例、瑞士2例、奥地利1例、法国1例。
- 溯源至土耳其胃内注射肉毒杆菌神经毒素减重治疗,通过接受该治疗的患者名单追踪病例。
- 首批12例德国病例中9例经实验室确诊,需高灵敏内肽酶检测法检出微量毒素。
核心结论
- 此次医源性肉毒中毒暴发与在土耳其接受胃内注射肉毒杆菌神经毒素减重治疗相关,欧洲多国协作完成溯源调查。
- 医生肉毒中毒报告要求对德国发现此次暴发至关重要。
- 应考虑修订肉毒中毒监测病例定义并纳入医源性肉毒中毒病例,因此类病例可能缺乏标准实验室确认但仍需公共卫生行动。
- 医疗操作中使用肉毒杆菌神经毒素的任何潜在风险需与操作的预期获益仔细权衡。
研究设计与样本
- 2023年3月在欧洲四国(德国、瑞士、奥地利、法国)发现34例医源性肉毒中毒相关病例,通过欧盟网络和《国际卫生条例》机制发布警报并开展欧洲协作调查。
- 通过接受该治疗的患者名单追踪病例,对首批12例德国病例进行实验室检查。
主要发现
- 德国发现30例、瑞士2例、奥地利1例、法国1例医源性肉毒中毒相关病例。
- 首批12例德国病例中实验室检查确认9例。
- 需应用创新且高灵敏的内肽酶检测法在患者血清中检出微量肉毒杆菌神经毒素。
关键数值与推荐
- 首批12例德国病例中9例经实验室确诊。
临床怎么用
- 医生肉毒中毒报告要求对德国发现此次暴发至关重要。
- 应考虑修订肉毒中毒监测病例定义并纳入医源性肉毒中毒病例,因此类病例可能缺乏标准实验室确认但仍需公共卫生行动。
- 医疗操作中使用肉毒杆菌神经毒素的任何潜在风险需与操作的预期获益仔细权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In March 2023, 34 associated cases of iatrogenic botulism were detected in Germany (30 cases), Switzerland (two cases), Austria (one case), and France (one case). An alert was rapidly disseminated via European Union networks and communication platforms (Food- and Waterborne Diseases and Zoonoses Network, EpiPulse, Early Warning and Response System) and the International Health Regulation mechanism; the outbreak was investigated in a European collaboration. We traced sources of the botulism outbreak to treatment of weight loss in Türkiye, involving intragastric injections of botulinum neurotoxin. Cases were traced using a list of patients who had received this treatment. Laboratory investigations of the first 12 German cases confirmed nine cases. The application of innovative and highly sensitive endopeptidase assays was necessary to detect minute traces of botulinum neurotoxin in patient sera. The botulism notification requirement for physicians was essential to detect this outbreak in Germany. The surveillance case definition of botulism should be revisited and inclusion of cases of iatrogenic botulism should be considered as these cases might lack standard laboratory confirmation yet warrant public health action. Any potential risks associated with the use of botulinum neurotoxins in medical procedures need to be carefully balanced with the expected benefits of the procedure.
引用
- Dorner MB, Wilking H, Skiba M, et al. A large travel-associated outbreak of iatrogenic botulism in four European countries following intragastric botulinum neurotoxin injections for weight reduction, Türkiye, February to March 2023. Euro Surveill. 2023. PMID: 37289431. doi:10.2807/1560-7917.ES.2023.28.23.2300203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。